Pancreatic Cancer Research

ResearcherFujita Health UniversityNo recent work listed

Aya Sugyo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5174-4478; OpenAlex author ID A5030574164. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers

Papers 14

  1. The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer… First author DOI 10.1016/j.tranon.2021.101285↗
  2. In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against… Co-author DOI 10.3390/ijms23105807↗
  3. Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreat… Co-author DOI 10.1097/mnm.0000000000001442↗
  4. Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer. Co-author DOI 10.1038/s41598-020-61056-5↗
  5. 64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer. Co-author DOI 10.2967/jnumed.118.225045↗
  6. Anti‑tissue factor antibody‑mediated immuno‑SPECT imaging of tissue factor expression in mouse models of pancreatic cancer. Co-author DOI 10.3892/or.2019.7017↗
  7. Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with 90Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a … Co-author DOI 10.3390/ijms19102979↗
  8. Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody. Co-author DOI 10.3748/wjg.v24.i48.5491↗
  9. Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor. Co-author DOI 10.3748/wjg.v23.i42.7551↗
  10. Immunotargeting of Integrin α6β4 for Single-Photon Emission Computed Tomography and Near-Infrared Fluorescence Imaging in a Pancreatic Cancer Model. Co-author DOI 10.1177/1536012115624917↗
  11. Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody. Co-author DOI 10.18632/oncotarget.9631↗
  12. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model. Co-author DOI 10.1097/mnm.0000000000000245↗
  13. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models. Co-author DOI 10.1371/journal.pone.0123761↗
  14. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0061230↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsuya Higashi · 9 shared papers, 2017–2022 · strength 0.91
  2. Tsuneo Saga · 8 shared papers, 2013–2019 · strength 0.50
  3. Yukie Yoshii · 4 shared papers, 2019–2022 · strength 0.42
  4. Mitsuyoshi Yoshimoto · 4 shared papers, 2019–2022 · strength 0.42
  5. Hiroki Matsumoto · 4 shared papers, 2019–2022 · strength 0.42
  6. Winn Aung U · 5 shared papers, 2016–2019 · strength 0.38
  7. Masahiro Yasunaga · 3 shared papers, 2018–2022 · strength 0.34
  8. Yasuhiro Matsumura · 3 shared papers, 2018–2022 · strength 0.34
  9. Fukiko Hihara · 3 shared papers, 2020–2022 · strength 0.32
  10. Chika Igarashi · 3 shared papers, 2020–2022 · strength 0.32
  11. Yoichi Takakusagi · 1 shared paper, 2022 · strength 0.16
  12. Makoto Ueno · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.